Hillel Galitzer - 31 Mar 2022 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Operating Officer
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Issuer symbol
ENTX
Transactions as of
31 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 16:05:58 UTC
Previous filing
14 Jan 2022
Next filing
25 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 31 Mar 2022 Ordinary Shares, par value NIS 0.0000769 per share 60,000 $2.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest over a four-year period that commenced on March 31, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.